MDWD (MediWound) Construction In Progress: $0.00 Mil (As of Mar. 2026)


MDWD MediWound Ltd MDWD
56 GF Score
Price $15.16
GF Value $12.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound Construction In Progress?

MediWound MDWD +2.19% 56 Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

MediWound Construction In Progress Historical Data

* Premium members only.

The historical data trend for MediWound's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediWound Construction In Progress Chart

MediWound Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MediWound Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDWD
56GF Score
MediWound Ltd MDWD
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediWound Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
MediWound (MDWD) has a Construction In Progress of $0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on MediWound and its competitors.
Is MediWound's Construction In Progress too high?
MediWound's current Construction In Progress is $0.00 Mil. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Construction In Progress compare to UNCY and ARCT?
MediWound's Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on MediWound and its competitors. MediWound's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Construction In Progress is $0.00 Mil. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For MediWound (MDWD), the current Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • Construction In Progress: $0.00 Mil
  • GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for MDWD

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16
Price
$12.44
GF Value